Arcturus Therapeutics vs Wave Life Sciences
ARCT and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and WVE compare
Wave Life Sciences is the larger company, worth 2.6 times as much as Arcturus Therapeutics ($617M against $238M).
Arcturus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −286% compared with −297% at Wave Life Sciences.
Wave Life Sciences scores higher on the StockData Score (10 against 9 for Arcturus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $238M | $617M |
| Share price | $8.36 | $3.13 |
| Change, 1 year | 2.8% | −55.0% |
| Change, 5 years | −77.1% | −27.4% |
| Beta (5Y) | 2.16 | 1.30 |
| Employees | 111 | 317 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× (better) | 8.7× |
| P/B | 1.4× (better) | 1.5× |
| FCF yield | −26.3% (better) | −33.8% |
| Fair value | $8.63 | $5.15 |
| Margin of safety | 3.1% | 39.2% (better) |
| Growth | ||
| Revenue growth (TTM) | −68.7% | – |
| Revenue growth, 5Y average | 53.8% (better) | 16.3% |
| Profitability | ||
| Operating margin | −311% (better) | −321% |
| Net margin | −286% (better) | −297% |
| FCF margin | −205% (better) | −294% |
| Return on equity | −44.4% (better) | −80.0% |
| Return on invested capital | −534% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.68 | 8.38 (better) |
| Altman Z-score | −1.08 | −0.98 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.9% | 92.6% |
| Held by insiders | 8.1% | 23.1% |
| Insider net buying, 12 months | – | $66.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 20.7% | 13.6% |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.